---
title: IVDR Compliance Checklist for IVD Startups in 2026
description: A phase-by-phase IVDR compliance checklist for IVD startups in 2026, from classification through CE mark, in the Subtract to Ship style.
authors: Tibor Zechmeister, Felix Lenhard
category: IVDR & In Vitro Diagnostics
primary_keyword: IVDR compliance checklist startup 2026
canonical_url: https://zechmeister-solutions.com/en/blog/ivdr-compliance-checklist-2026
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# IVDR Compliance Checklist for IVD Startups in 2026

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **A useful IVDR compliance checklist is not a long list. It is a short, ordered sequence of phases that each have a clear exit criterion. For an in vitro diagnostic startup in 2026, the phases are qualify and classify the device, build the quality management system, draft technical documentation with a performance evaluation plan and performance evaluation report, secure notified body engagement (or self-declare if Class A non-sterile), generate performance evaluation evidence, build the post-market surveillance plan, and affix the CE mark. This post walks each phase in the Subtract to Ship style. Every step traces back to a specific IVDR article or annex. Nothing is held back.**

**By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.**

---

## TL;DR

- The IVDR (Regulation (EU) 2017/746) sets out the rules for in vitro diagnostic medical devices placed on the European Union market. It applies in full.
- Compliance is best approached as a sequence of phases with exit criteria, not as a long flat checklist with no order.
- Every IVD startup has to qualify the device, classify it under the IVDR rules, and justify the classification in writing before anything else.
- The quality management system is built on EN ISO 13485:2016+A11:2021 and integrated from day one. Retrofitting a QMS is more expensive than building one.
- Clinical evaluation under the MDR becomes performance evaluation under the IVDR, documented in a performance evaluation plan (PEP) and a performance evaluation report (PER).
- Notified body engagement is mandatory for every class above Class A non-sterile. The IVDR notified body pool is small and should be planned for accordingly.
- Post-market surveillance and vigilance are regulatory obligations that start the moment the device is on the market, not optional.
- Subtract to Ship means finishing each phase cleanly before starting the next, and refusing to add steps that do not reduce risk or produce required evidence.

---

## Why this matters

An in vitro diagnostic startup in 2026 is operating in a narrower and more fragile regulatory environment than an MDR medical device startup. The IVDR designated notified body pool is smaller, the classification rules are fewer but less forgiving, and the evidence burden for performance evaluation has caught many founders by surprise. A compliance checklist that is just a bullet list of requirements is not useful here. What is useful is a phase-by-phase checklist that can be held up against the startup's current state and answer one question. What is the next thing we have to finish before we can move on?

Tibor has guided founders through the IVDR sequence often enough to see the same failure modes repeating. The biggest one. Teams that try to execute every phase in parallel, run out of cash in phase four, and discover that phases one through three were never actually finished. The Subtract to Ship approach inverts this. Finish one phase, close it, move on. Do not reopen finished phases unless new evidence forces it.

This post is the closing post of the IVDR mini-cluster on this blog. It is written so a founder can read it standalone and know what the path looks like end to end. The earlier posts in the cluster go deeper on individual questions. The [notified body bottleneck post](/blog/ivdr-notified-body-bottleneck) in particular is the paired deep dive for phase four below.

## What the IVDR actually says

The IVDR is Regulation (EU) 2017/746. It sets out general obligations for manufacturers in Article 10, a classification system in Article 47 and Annex VIII, conformity assessment routes in Articles 48 and 49, performance evaluation requirements in Article 56 and Annex XIII, and the general safety and performance requirements in Annex I. Technical documentation requirements are in Annex II. These references are the backbone of every phase in the checklist below.

Two points that founders most often miss. First, the IVDR classification rules are fewer in number than the MDR rules but the classification logic turns on what the device is intended to detect or diagnose and how the result is used. The intended purpose sentence matters enormously. Second, clinical evaluation as it exists under the MDR is not the same construct as performance evaluation under the IVDR. Performance evaluation is about scientific validity, analytical performance, and clinical performance, evidenced through samples rather than through live clinical investigations in the MDR sense.

## The phase-by-phase checklist

### Phase 1. Qualify and classify

The first question is whether the product is an in vitro diagnostic medical device at all. IVDR Article 2(2) defines an IVD as a device intended to be used in vitro for the examination of specimens derived from the human body, for specific purposes related to diagnosis, monitoring, prediction, and so on. If the device does not meet that definition, it is not in scope of the IVDR. If it does, the founder proceeds to classification.

Classification follows IVDR Annex VIII. The rules are fewer than in MDR Annex VIII, but the outcome has large consequences. Class A non-sterile devices are self-declared. Everything else needs a notified body. The exit criterion for this phase is a written classification justification document that cites the specific IVDR rule, restates the intended purpose, and reaches a class decision. Do not leave this phase without it.

Subtract to Ship move. If the classification depends on an intended purpose phrasing that can be narrowed without damaging the commercial proposition, narrow it. A tighter intended purpose is often a lower class. A lower class is often a shorter path.

### Phase 2. Build the quality management system

Under IVDR Article 10(8) the manufacturer is required to establish, document, implement, maintain, keep up to date, and continually improve a quality management system. In practice this means building a QMS that conforms to EN ISO 13485:2016+A11:2021 and covers the specific IVDR obligations that go beyond the ISO standard. The QMS is not a Phase 2 activity that finishes. It is a Phase 2 activity that starts and then runs forever. The exit criterion is that the QMS is documented and operational, not that it is complete, because complete is not a state a QMS ever reaches.

Subtract to Ship move. Do not buy an off-the-shelf QMS template and paste the company name on it. Build the minimum set of procedures that actually describe how the team works, and expand from there. An honest small QMS is more valuable than an aspirational large one.

### Phase 3. Draft technical documentation with PEP and PER

Technical documentation requirements sit in IVDR Annexes II and III. The two documents that most distinguish IVDR from MDR are the performance evaluation plan (PEP) and the performance evaluation report (PER), both grounded in Article 56 and Annex XIII. The PEP sets out how the manufacturer will demonstrate scientific validity, analytical performance, and clinical performance. The PER documents the results.

Risk management runs in parallel, based on EN ISO 14971:2019+A11:2021, and feeds into the general safety and performance requirements evidence in Annex I. The exit criterion for this phase is a technical documentation file that a reviewer can follow without asking the founder for context on every page.

Subtract to Ship move. Write the PEP first and the PER outline second, before running the studies. A PEP that is written after the studies are done is a retrospective rationalisation and notified bodies can usually tell.

### Phase 4. Secure notified body engagement

For every class above Class A non-sterile, this phase is unavoidable. Under IVDR Articles 48 and 49 the manufacturer applies to a designated notified body, enters a contract, and undergoes conformity assessment appropriate to the class.

Tibor has observed that the IVDR notified body pool is materially smaller than the MDR pool, which makes this phase longer and less predictable than founders expect. The honest plan is to open scoping conversations early, before the technical documentation file is complete, and to treat notified body calendar slots as scarce resources. The paired deep dive is the [IVDR notified body bottleneck post](/blog/ivdr-notified-body-bottleneck).

If the device is Class A non-sterile, this phase is replaced by self-declaration against the IVDR general safety and performance requirements. Self-declaration is not a synonym for no documentation. The technical documentation still has to exist, and the founder still signs the EU declaration of conformity personally.

### Phase 5. Generate performance evaluation evidence

This is where the PEP is executed. Scientific validity is usually literature-led. Analytical performance is usually studies on characterised samples. Clinical performance varies by device class and intended purpose. Felix has watched startups underestimate the calendar of this phase more often than the cost. The studies themselves take time, the analysis takes more time, and integrating the results into the PER takes more time than the founder assumed.

The exit criterion. The PER is written, the evidence is traceable, and the gaps are named. A PER that pretends there are no gaps is worse than a PER that names them and justifies why they do not compromise the benefit-risk determination.

### Phase 6. Post-market surveillance plan

IVDR Articles 78 to 81 lay out the post-market surveillance obligations. Every manufacturer needs a post-market surveillance plan proportionate to the class and intended purpose of the device. For Class C and D devices a periodic safety update report (PSUR) is required. For Class A and B a post-market surveillance report is required instead.

The exit criterion for this phase is a documented PMS plan that is ready to activate the day the device reaches the market, plus the vigilance procedures that handle serious incidents and field safety corrective actions.

Subtract to Ship move. Do not build a PMS plan that promises activities the company cannot afford to execute. Build the minimum PMS plan that meets the regulation, and improve it once real-world data starts arriving.

### Phase 7. Affix the CE mark

The EU declaration of conformity is signed. The CE mark is applied according to IVDR Article 18. The device is registered in EUDAMED as required. The manufacturer, importer, and authorised representative obligations under Articles 10, 11, and 13 are in place. The device is on the market. Phase 7 does not finish the compliance work. It starts the maintenance mode that will last for the life of the device.

## A worked example

A small IVD startup is building a Class B assay for biomarker detection in serum. Phase 1 lands the classification in writing with rule citation, intended purpose, and rationale. Phase 2 gets a working QMS in place with the core procedures and training records. Phase 3 produces a technical documentation file with a PEP structured around the scientific validity, analytical performance, and clinical performance triad. Phase 4 opens with notified body scoping calls at month 12 instead of month 18, because the team has read the IVDR notified body bottleneck post and acts on it. Phase 5 executes the performance evaluation studies on the timeline the notified body indicated it could review them on. Phase 6 activates the PMS plan on the day the declaration of conformity is signed. Phase 7 places the CE mark.

The total elapsed time is longer than the founder initially hoped. It is also realistic, defensible, and does not leave the company exposed to a rebuild halfway through.

## Reality Check

1. Is the device qualification and classification written down with specific rule citation, or is it assumed?
2. Does the QMS actually describe how the team works today, or is it a template that no one uses?
3. Is there a performance evaluation plan, written before the studies, or will the PEP be retrofitted after the fact?
4. Has anyone on the team talked to a designated IVDR notified body directly, or is the plan built on published information alone?
5. If the earliest realistic notified body engagement is 12 months out, does the fundraising runway cover it with buffer?
6. Is the post-market surveillance plan proportionate and executable, or does it promise activities the company cannot resource?
7. If an auditor walked in tomorrow, could the founder hand them a file that tells a coherent story from intended purpose to PER?
8. Which phase is currently unfinished, and what is the exit criterion that will close it?

## Frequently Asked Questions

**What is the difference between clinical evaluation and performance evaluation?**
Under the MDR, clinical evaluation demonstrates that a medical device is safe and performs as intended on the basis of clinical data, often from clinical investigations on human subjects. Under the IVDR, performance evaluation demonstrates scientific validity, analytical performance, and clinical performance, usually on the basis of samples rather than live subjects. Article 56 and Annex XIII of the IVDR set out the requirement.

**Can an IVD startup self-certify under the IVDR?**
Only if the device is Class A and non-sterile. Everything else requires a designated notified body. This is narrower than the self-declared route available for Class I non-sterile non-measuring non-reusable surgical devices under the MDR.

**How long does IVDR compliance take end to end for a Class B device?**
There is no single answer, but realistic ranges are 18 to 30 months from a standing start to CE mark for a well-executed Class B project. Much of the variance is driven by performance evaluation study design and by notified body availability.

**Is EUDAMED registration mandatory for IVDs?**
Registration obligations under the IVDR and the corresponding EUDAMED modules apply as the modules become functional. Founders should check the current state of EUDAMED mandatory use before the CE mark phase and plan their registration sequence accordingly.

**What is the single highest-leverage move an IVD founder can make in 2026?**
Tibor's answer. Finish phase 1 properly and in writing, so every subsequent phase is built on a classification rationale that will survive contact with a notified body.

**Does Subtract to Ship mean cutting corners?**
No. It means refusing to add steps that do not reduce risk or produce required evidence. Every IVDR requirement still has to be met. The methodology is about sequencing and focus, not about removing work the regulation actually demands.

## Related reading

- [IVDR and the Notified Body Bottleneck](/blog/ivdr-notified-body-bottleneck). The paired deep dive on phase 4 of this checklist.
- [What Is a Notified Body](/blog/what-is-notified-body). Foundational explainer.
- [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr). The broader methodology this post applies to the IVDR context.
- [Strategic Approach to Classification: Plan Before You Build](/blog/strategic-approach-classification-plan-before-build). The classification sequencing logic from the MDR cluster, which applies directly to IVDR phase 1.
- [Notified Body Bottleneck Under the MDR](/blog/notified-body-bottleneck). The MDR comparison point for the IVDR capacity discussion.

## Sources

1. Regulation (EU) 2017/746 on in vitro diagnostic medical devices, consolidated text. Articles 5, 10, 47, 48, 49, 56, 78 to 81. Annexes I, II, VIII, XIII.
2. EN ISO 13485:2016+A11:2021, quality management systems for medical devices.
3. EN ISO 14971:2019+A11:2021, application of risk management to medical devices.
4. European Commission, NANDO database of notified bodies designated under Regulation (EU) 2017/746.
5. Tibor Zechmeister, direct experience guiding IVD companies through the IVDR conformity assessment sequence, 2022 to 2026.

---

*This post is part of the [IVDR & In Vitro Diagnostics](https://zechmeister-solutions.com/en/blog/category/ivdr) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*